Visit the Khiron Life Sciences Investor Dashboard and stay up to date with data-driven, fact based due diligence for active traders and investors.
Khiron First Company to Receive Licence for Cultivation of Medical Cannabis in Colombia
TORONTO, Sept. 26, 2017 (GLOBE NEWSWIRE) — Khiron Life Sciences Corp. (“Khiron” or the “Company”) reports that its wholly owned subsidiary, Khiron Colombia SAS, has been granted the first licence ever issued by the Ministry of Justice for the cultivation of medical cannabis in Colombia. The granting of this licence positions the Company as the first grower of low tetrahydrocannabinol (“THC”) medical cannabis in the country, and enables the Company to produce low THC based extracts for domestic and international consumption. The Company currently has two additional licence applications pending approval by the Ministry of Justice and Ministry of Health, and anticipates the issuance of these licences in the near term. These licences would enable the cultivation of high THC based cannabis and production of high THC based cannabis extracts. Similar to the licence granted for low THC based cannabis by the Ministry of Justice, the Company was the first organization to submit licence applications for the cultivation of high THC based cannabis and production of high THC based cannabis extracts, under the current regulations.
We are honored by the confidence bestowed upon us by the government of Colombia, and fully accept the responsibility to deliver on our commitment to produce quality products, support patients and healthcare professionals, and to be in full regulatory compliance. We are proud to be a leader in Colombia’s entrance to this emerging global industry.
Mr. Alvaro Torres, President and CEO
I would like to personally thank all members of our team for their tireless efforts in reaching this milestone. We look forward to continuing our dialogue with the government of Colombia to ensure the attainment of its objectives for the medical cannabis industry.
Colombian Medical Cannabis Regulations
The Colombian government enacted the law for medical cannabis in June of 2016, and subsequently in April of 2017, issued a decree that sets forth the framework for the cultivation, production, and domestic and international distribution of low and high THC based medical cannabis extracts. This decree was further defined by the enactment of four resolutions specifying the application fees, security requirements, quality controls, and responsibilities of the license holders and government administrators.
The ground-breaking regulatory framework enacted by the government of Colombia sets the standard for other jurisdictions in Latin America. The Colombian regulations focus on extracts to generate a purely medical product market, and provide for product quality and consistency through the country’s federal food and drug regulator. In compliance with international laws, these regulations also provide for legal exportation thereby leveraging the agricultural and scientific competitive advantages of the country.
About Khiron Life Sciences Corp.
Khiron Life Sciences Corp. is a Canadian integrated medical cannabis company with its core operations in Colombia. Khiron combines leading international scientific expertise, agricultural advantages, and branded product market entrance experience to address the unmet medical needs in a market of over 620 million people in Latin America.
The most reliable, fact-based information on Khiron Life Sciences found only on its Investor Dashboard.